Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study

Age Requirement: 18 to 55

This is a national study looking at how safe and effective oral budesonide suspension is for eosinophilic esophagitis. Approximately 60 sites are participating. If you are 18 to 55 years of age, have difficulty swallowing or have been diagnosed with eosinophilic esophagitis you may qualify for this study.

This clinical study will last for about 26 weeks and during this time you will be asked to visit the study center up to eight times. You will have six office visits and two upper endoscopies. At the study visits, various tests and checks will be carried out, so that the study doctor can monitor your health.

For study details see A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved.


  • Financial compensation is provided.
  • Investigational medication is provided at no charge.
  • Study-related care from a doctor at no charge.


Adriana Hernandez-Garcia adh1@bcm.eduPhone 1: (713) 986-5634
IRB: h-39488




Mar 08, 2017